Background: TNBC represents a heterogeneous subgroup of BC with poor prognosis and frequently resistant to CT.
introduction BC is the most commonly occurring cancer in women. One hundred and seventy thousand (12.2%) of the newly 1.38 million diagnosed BC cases each year are defined TNBC [1, 2] . TNBC represents a subgroup of BCs that lack significant expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor-2 (HER2) TNBCs are generally considered to be aggressive tumours that often occur at a young age [3] . Recent studies, however, suggest that TNBC may represent a heterogeneous group of tumours with regards to gene expression, clinical presentation, epidemiology, histology, radiology, prognosis and response to treatment [2] [3] [4] [5] .
The management of TNBC remains a significant clinical challenge, hindered by the inability of these tumours to respond to targeted therapeutic agents [2] [3] [4] . As TNBC appears to represent a more diverse population than originally thought, further sub-stratification may help identify patients with a subtype of TNBC more or less likely to respond to chemotherapy.
Recent studies have shown Bcl2 protein and gene expression to be a promising prognostic and predictive marker in human cancers [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] especially in hormone receptor-positive, nodenegative BC [16, 17] . High Bcl2 level is associated with improved BC outcome.
The role of Bcl2 in TNBC, however, is not well defined. In addition, few studies have investigated the association between Bcl2 status and response to chemotherapeutic agents, including anthracycline in BC patients [10] . For instance, in diffuse large B-cell lymphoma (DLBCL) with MYC/Bcl2 co-expression a worse prognosis was seen in patients treated with an ATC-CT (R-CHOP; Rituximab-cyclophosphamide, doxorubicin, vincristine and prednisolone).
In this study, we have investigated the role of Bcl2 as a prognostic marker in a large cohort of TNBC. We have also studied the role of Bcl2 as a surrogate predictive marker of response to chemotherapy prescribed in the adjuvant or neoadjuvant setting in patients with either early primary-TNBC (EP-TNBC) or primary locally advanced triple negative breast cancer (PLA-TNBC).
materials and methods
For materials and methods section, see supplementary material, available at Annals of Oncology online. results early primary-TNBC cohort EP-TNBC patients were all female and their median age was 51 years (range 28-71 years). Their median follow-up was 107 months (range 2-243 months).
clinico-pathological features of bcl2 expression in EP-TNBC. Negative Bcl2 expression (Bcl2-; Figure 1C -E) was observed in 421 of 600 (70.2%) of EP-TNBC tumours and was significantly associated with high mitotic index (P = 0.005), high levels of P-Cadherin (P = 0.007), E-Cadherin (P = 0.045), CK 19 (P = 0.001) and HER3 (P < 0.0001). While Bcl2 positive expression (Bcl2+) was significantly associated with high expression of p27 (P = 0.01), MDM4 (P < 0.0001), and sperm associated antigen 5 (SPAG5; P = 0.004) ( Table 1) .
bcl2 is an independent prognostic biomarker in EP-TNBC. Bcl2-was strongly associated with an adverse outcome at 10 years and nearly doubles the risk of death from EP-BC (HR 1.71; 95% confidence interval (CI) 1.21-2.41; P = 0.002) and recurrence (HR 1.79; 95% CI 1.34-2.38; P = 0.0005); (Figure 1F-H) . After controlling for chemotherapy, traditional pathological prognostic factors and other potential confounders, Bcl2 was confirmed as an independent prognostic factor for both DFS (HR 1.69; 95% CI 1.26-2.27; P = 0.0004) and BCSS (HR 1.64; 95% CI 1.15-2.32; P = 0.006) at 10 years ( Table 2 ). The EP-TNBC cohort was further subdivided into three patient Figure S1E -F, available at Annals of Oncology online). Again Bcl2-was associated with approximately twice the risk of death from EP-BC (HR 2.25; 95% CI 1.40-3.59; P = 0.001) and also of recurrence (HR 2.45; 95% CI 1.61-3.71; P = 0.00002) in patients who did not receive chemotherapy. In patients treated with CMF a significant association was demonstrated between Bcl2 status and clinical outcome; Bcl2-had a shorter DFS (log rank 2.66, P = 0.031) and BCSS (log rank 3.43, P = 0.05).
bcl2 is a predictor of outcome after adjuvant ATC-CT. In EP-TNBC patients who received ATC-CT, Bcl2-tumours had a clinical outcome similar to those with Bcl2+ phenotype (supplementary Figure S1E -F, available at Annals of Oncology online). Both BCCS and DFS were longer in Bcl2-patients treated with an ATC-CT when compared with those Bcl2-patients who didn't receive chemotherapy or who were treated with CMF (Figure 2A-D) .
Bcl2-TNBC patients had prolonged BCSS and DFS when they were exposed to ATC-CT compared with those who either received CMF or did not received any chemotherapy (Figure 2A-D) . For example 42% of patients who were Bcl2-and either did not receive any chemotherapy or received CMF had died of BC at 10 years compared with 25% of Bcl2-patients who were treated with ATC-CT. For Bcl2-/TNBC patients, exposure to ATC-CT reduced the risk of death (HR 0.53; 95% CI 0.35-0.80, P = 0.002) and recurrence (HR 0.61; 95% CI 0.44-0.84, P = 0.003) by 40%-50%.
No benefit was demonstrated from prescribing ATC-CT in Bcl2+ EP-TNBC (supplementary Figue S2A-C, available at Annals of Oncology online). Even those of high-risk (NPI >3.4) Bcl2+ EP-TNBC patients who were exposed to ATC-CT had double the risk of recurrence (HR 1.85; 95% CI 1.03-3.34, Multivariate regression analysis, after controlling for patient age at diagnosis, tumour stage, grade, size and p53 status, showed that Bcl2-expression is an independent predictor of pCR of LA-TNBC (HR 4.53; 95% CI 1.5-13.8 P = 0.008); (supplementary Figue S3B, available at Annals of Oncology online). discussion TNBC encompasses a subpopulation of BC patients traditionally considered to have a poor prognosis [3] . Neither the classical pathological variables nor the modern molecular assays, have shown prognostic value in this patient group [2] [3] [4] [5] 17] . Current research is focused on the identification of biological markers that could be used to tailor treatment to individual patients with TNBC. The results of our study show Bcl2 to be a promising prognostic and predictive marker in TNBC. This adds to an increasing body of evidence to support that routine assessment of Bcl2 status in TNBC patients may refine the outcome, both as a prognostic and predictive factor.
Although the potential importance of Bcl2 as a prognostic factor in BC has been investigated in previous studies [8, 9, 15, 16] , our study has reported the prognostic importance of this marker in a large number of TNBC cases (over 700 patients). We have shown that loss of Bcl2 nearly doubles the risk of both death and recurrence from TNBC in agreement with earlier studies in mixed BC cohorts [8, 9, 15, 16] . Contrary to our findings, Tawfik et al. found Bcl2+ TNBC had a worse prognosis than Bcl2-TNBC. The reason for these differences is not clear but the smaller patient sample, differences in treatment protocols or other factors in the study by Tawfik et al. may play a role. Our study has also shown that Bcl2 status could help predict the outcome of treatment. In Bcl2-/TNBC patients, both BCSS and DFS are improved if patients are treated with an anthracycline. This association is not seen in Bcl2+/TNBC patients. In fact in the latter population there is some evidence to suggest that these patients have worse DFS when treated with an anthracycline. Similar results have been reported by Bouchalova et al. who analysed the response to AC-ACT in a small cohort of TNBC patients. The findings of this study are in agreement with our results demonstrating that high Bcl2 expression is associated with worse relapse free and overall survival (OS) in patients treated with adjuvant anthracyclinebased treatment. Again the results from the multivariate analysis of this study show Bcl2 status, size and LN stage to be predictive of both OS and DFS [26] in common with our findings. Furthermore, similar associations have been seen between Bcl2 status and anthracycline response in other tumours. For example DLBCL patients with both MYC and Bcl2 co-expression had a worse DFS and OS when treated with standard R-CHOP chemotherapy [6] .
Interestingly in our study the benefit from chemotherapy in the Bcl2-patient group was only seen when they were treated with an anthracycline and not from CMF. All patients who received an anthracycline-based regimen will have been given FEC-combination. As FEC contains 5-FU and cyclophosphamide in common with CMF the only different agent between the two regimens is the anthracycline, in this case epirubicin. The significant difference observed between the no chemotherapy/CMF group and the anthracycline treated group is therefore most likely due to the addition of epirubicin, although could be a combination effect of the drugs used. Recently, Buchholz et al. found that 27% of Bcl-2 negative BC had achieved pCR to Doxorubicin-based neoadjuvant chemotherapy versus 4% of Bcl-2 positive (P = 0.004).
We have shown Bcl2-expression to be an independent predictor of pCR in PLA-TNBC. Bcl2-/TNBC patients were 
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significantly more likely to have a pCR than patients with Bcl2+ expression. These findings are similar to early reports in mixed BC cohorts (i.e. both TNBC and non-TNBC [7] . Von Minckwitz et al also found Bcl2-to be associated with pCR in patients with primary-BC treated with dose-dense doxorubicin and docetaxel chemotherapy with or without endocrine treatment. As a pCR following neoadjuvant ATC-CT has been shown to be associated with an improved outcome, our findings suggest that staining for Bcl2 status in TNBC patients could help identify a cohort of patients who would be ideal for neoadjuvant ATC-CT.
As evidenced by our results, and those from earlier studies, patients with Bcl2-/TNBC tumours gain significant benefit from anthracycline treatment. The explanation behind this finding is likely to be complex and involve the multiple functions of Bcl2. The Bcl2 protein acts as both an anti-apoptotic factor and also prolongs cell cycle at G0 [11, 13, 14] , and therefore, Bcl2+ cells are more likely to recover from damage caused by chemotherapy. Bcl2-tumours however respond to treatment, probably through accumulation of DNA damage, abnormal mitoses and subsequent mitotic catastrophe. The mechanisms of mitotic catastrophe are unknown, but it likely results from a combination of deficient cell-cycle checkpoints (in particular the DNA structure checkpoints and the spindle assembly checkpoint) and cellular damage catastrophe. Conversely, non-responding Bcl2-tumours could escape the response through accumulation of genetic abnormalities that would not lead to a mitotic catastrophe but rather to aneuploidy and subsequent growth advantage. Interestingly, we found that loss of Bcl2 in TNBC was associated with higher mitotic index, low levels of p27 (G0/G1 check protein), MDM4 ( p53-inhibitory factor) and SPAG5 which is essential for cell cycle progression and fidelity of chromosomal segregation.
Bcl2-/LANBC patients treated with neoadjuvant ATC-CT are more likely to have a pCR than Bcl2+ patients. However, in those patients who do not achieve a pCR prognosis is worse in the Bcl2-group. Clearly, these Bcl2-patients represent a cohort who has demonstrated limited response to anthracycline-based treatment and targeting alternative pathways in these patients warrants further investigation.
We found that loss of Bcl2 expression in TNBC was significantly related to increased levels of CK19, P-cadherin, E-cadherin and HER3. The differential expression of these biomarkers could be a reflection of the molecular subclasses of TNBC and could also have biological and therapeutic implications. Previous studies have suggested P-cadherin as a promising antibody therapeutic target or as a possible target for immunotherapy of pancreatic, gastric and colorectal cancers relapse. In agreement with an early study in basal BC, 75% of our TNBC showed overexpression of P-cadherin and that is highly associated with loss of Bcl2 compared with 35% of mixed BC. Given the high incidence of P-cadherin overexpression in TNBC Bcl2-tumours and that was associated with poor clinical outcome (data not shown), P-cadherin targeting may warrant further investigation in this group of TNBC.
Given that ∼40% of our TNBC cases show overexpression of HER3, and that this is highly associated with the absence of Bcl2, suggests a potential role of HER3 targeting agents in specific subtypes of TNBC. Recent studies suggest that combination treatment with trastuzumab and pertuzumab may be particularly efficacious in HER2-amplified BC; however, no data are available for TNBC particularly in the HER2-enriched subgroup.
Although prognosis is better in Bcl2+/TNBC mortality rates can still be in excess of 20% at 15 years. Our data demonstrate that the benefit seen in Bcl2-/TNBC in response to anthracycline-based treatment is not observed in Bcl2+ patients. This would suggest that a different treatment strategy is required in these patients. In conclusion, adding Bcl2 to the panel of markers used in current clinical practice (ER, PR and HER2) could provide both prognostic and predictive information in patients with TNBC. Patients with Bcl2-/TNBC phenotype have a worse prognosis than Bcl2+/TNBC patients but appear to benefit from ATC-CT. The optimal management of Bcl2 +/TNBC tumours is yet to be defined. A prospective study is required to validate these results and to investigate potential therapeutic targets in Bcl2+/TNBC patients. In addition, Bcl2 status could be investigated as a possible predictive marker for chemotherapy in non-TNBC high-risk BC subsets. 
